SLS
SELLAS Life Sciences Group, Inc. NASDAQ$5.02
Mkt Cap $715.1M
52w Low $1.36
76.6% of range
52w High $6.14
50d MA $4.92
200d MA $2.97
P/E (TTM)
-19.7x
EV/EBITDA
-12.0x
P/B
7.6x
Debt/Equity
0.0x
ROE
-37.9%
P/FCF
-14.5x
RSI (14)
—
ATR (14)
—
Beta
2.23
50d MA
$4.92
200d MA
$2.97
Avg Volume
6.4M
About
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 c…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.06 | -0.05 | +21.0% | 5.20 | +7.7% | -8.5% | +5.4% | -3.8% | +1.9% | -4.8% | -4.0% | — |
| Nov 12, 2025 | AMC | -0.06 | -0.06 | +5.2% | 1.49 | +0.7% | -2.0% | -4.0% | -5.4% | +6.7% | +2.0% | +36.2% | — |
| Aug 12, 2025 | AMC | -0.08 | -0.07 | +16.0% | 1.61 | +0.6% | -3.7% | -3.7% | +1.2% | +7.5% | +5.6% | +17.4% | — |
| May 13, 2025 | AMC | -0.10 | -0.07 | +30.0% | 1.41 | +4.3% | +7.1% | +13.5% | +15.6% | +24.1% | +37.6% | +17.0% | — |
| Mar 20, 2025 | AMC | -0.11 | -0.08 | +27.3% | 1.21 | -6.6% | -0.8% | +1.7% | +0.8% | -2.5% | -4.1% | +6.6% | — |
| Nov 13, 2024 | AMC | -0.13 | -0.10 | +23.1% | 1.27 | +0.8% | +0.0% | +3.9% | +1.6% | +1.6% | -2.4% | -31.3% | — |
| Aug 13, 2024 | AMC | -0.16 | -0.13 | +18.8% | 1.19 | +0.0% | +0.8% | +6.7% | +10.9% | +16.8% | +10.1% | +11.8% | — |
| May 14, 2024 | AMC | -0.16 | -0.21 | -31.2% | 1.37 | -1.5% | +7.3% | +7.3% | +6.6% | +8.0% | +3.6% | +5.8% | — |
| Mar 28, 2024 | AMC | 0.09 | -0.25 | -388.5% | 1.01 | +2.0% | +5.9% | +16.8% | +29.7% | +27.7% | +32.7% | +19.8% | — |
| Nov 9, 2023 | AMC | -0.03 | -0.33 | -1200.2% | 0.91 | -2.2% | -0.2% | -3.3% | -0.3% | +6.6% | +1.2% | +13.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Maxim Group | Maintains | Buy → Buy | — | $5.48 | $5.52 | +0.7% | -8.2% | -2.0% | -2.2% | -8.0% | -9.7% |
| Jul 16 | Maxim Group | Maintains | Buy → Buy | — | $1.90 | $1.91 | +0.5% | +1.1% | +0.0% | -6.8% | -2.6% | -3.2% |
| Nov 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.97 | $0.99 | +2.0% | +4.1% | +8.2% | +3.1% | +9.3% | +8.2% |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.44 | $1.42 | -1.4% | +2.1% | +10.4% | +4.9% | +4.9% | +5.6% |
| Nov 15 | Alliance Global Partners | Maintains | Buy → Buy | — | $2.55 | $2.50 | -2.0% | -12.2% | -3.9% | +3.1% | +2.0% | +1.2% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.32 | $2.39 | +3.0% | -4.7% | -2.6% | -3.9% | -5.2% | +2.2% |
| Jul 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.60 | $9.00 | +4.7% | +8.1% | +4.5% | +2.1% | +0.8% | -1.2% |
| Nov 18 | Alliance Global Partners | Maintains | Buy → Buy | — | $5.15 | $4.23 | -17.9% | -18.4% | -14.8% | -16.5% | -22.3% | -23.9% |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.15 | $4.23 | -17.9% | -18.4% | -14.8% | -16.5% | -22.3% | -23.9% |
| Nov 18 | Maxim Group | Upgrade | Hold → Buy | — | $5.15 | $4.23 | -17.9% | -18.4% | -14.8% | -16.5% | -22.3% | -23.9% |
Recent Filings
8-K
Unknown — 8-K Filing
SELLAS anticipates 2026 clinical milestones in its AML programs could validate its late-stage pipeline and potentially drive significant stock movement based on trial progress.
Mar 19
8-K
Unknown — 8-K Filing
This appears to be a technical XBRL metadata filing with no material business information, so it has no direct stock impact—investors should monitor actual 8-K disclosures instead.
Mar 11
Data updated apr 27, 2026 1:47am
· Source: massive.com